Senti Biosciences, Inc.
SNTI
Market ClosedWatchlist
SNTI RSI Chart
SNTI Valuation
SNTI Price/Sales (Trailing)
SNTI Profitability
SNTI Fundamentals
SNTI Revenue
SNTI Earnings
Price Action
Last 7 days
5.6%
Last 30 days
31.0%
SNTI Financial Health
SNTI Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2023 | 4.5M | 4.0M | 2.6M | 0 |
| 2022 | 3.8M | 4.4M | 5.0M | 4.3M |
| 2021 | 1.1M | 1.7M | 2.2M | 2.8M |
| 2020 | 0 | 0 | 0 | 566.0K |
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for SNTI
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
| Oct 03, 2022 | knobelman deborah | acquired | - | - | 30,000 | chief financial officer |
| Jun 08, 2022 | epstein david r | acquired | - | - | 112,519 | - |
| Jun 08, 2022 | farokhzad omid | acquired | - | - | 5,750,000 | - |
| Jun 08, 2022 | farokhzad omid | acquired | 2,500,000 | 10.00 | 250,000 | - |
| Jun 08, 2022 | farokhzad omid | sold | - | - | -4,518,100 | - |
| Jun 08, 2022 | dynamics sponsor llc | acquired | - | - | 5,750,000 | - |
| Jun 08, 2022 | dynamics sponsor llc | sold | - | - | -6,465,500 | - |
Which funds bought or sold SNTI recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
| Nov 21, 2023 | COMERICA BANK | new | - | 20.00 | 20.00 | -% |
| Nov 15, 2023 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | reduced | -5.85 | -26,374 | 47,130 | -% |
| Nov 15, 2023 | MORGAN STANLEY | reduced | -99.99 | -10,659 | - | -% |
| Nov 15, 2023 | HARBOUR INVESTMENTS, INC. | unchanged | - | -2,140 | 4,130 | -% |
| Nov 15, 2023 | Virtu Financial LLC | sold off | -100 | -22,000 | - | -% |
| Nov 14, 2023 | RENAISSANCE TECHNOLOGIES LLC | sold off | -100 | -11,000 | - | -% |
| Nov 14, 2023 | STATE STREET CORP | unchanged | - | -7,777 | 16,606 | -% |
| Nov 14, 2023 | PRICE T ROWE ASSOCIATES INC /MD/ | reduced | -7.26 | -780,000 | 1,337,000 | -% |
| Nov 14, 2023 | BANK OF AMERICA CORP /DE/ | added | 14,844 | 12,953 | 13,086 | -% |
| Nov 14, 2023 | Omega Fund Management, LLC | unchanged | - | -41,900 | 80,862 | 0.07% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Recent SEC filings of Senti Biosciences, Inc.
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Nov 14, 2023 | 10-Q | Quarterly Report | |
| Nov 13, 2023 | 8-K | Current Report | |
| Nov 13, 2023 | 424B3 | Prospectus Filed | |
| Nov 13, 2023 | 424B3 | Prospectus Filed | |
| Nov 06, 2023 | 8-K | Current Report | |
| Nov 03, 2023 | EFFECT | EFFECT | |
| Nov 03, 2023 | EFFECT | EFFECT | |
| Nov 01, 2023 | POS AM | POS AM | |
| Nov 01, 2023 | POS AM | POS AM |
Peers (Alternatives to Senti Biosciences, Inc.)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
HILS | 31.4B | - | 4.92% | 426363.59% | -3.6K | 218.4K | - | -102.45% |
MRNA | 30.7B | 10.7B | 11.84% | -53.56% | -8.86 | 2.88 | -53.67% | -129.46% |
ALNY | 22.0B | 1.7B | 4.71% | -20.32% | -43.06 | 12.74 | 79.37% | 56.87% |
BMRN | 17.7B | 2.3B | 23.54% | -7.88% | 120.62 | 7.68 | 15.05% | 75.21% |
INCY | 12.4B | 3.6B | 1.56% | -32.86% | 29.22 | 3.44 | 8.35% | -51.49% |
| MID-CAP | ||||||||
APLS | 7.5B | 272.9M | 38.55% | 34.32% | -12.3 | 27.32 | 141.38% | 4.43% |
BBIO | 5.6B | - | 16.25% | 246.63% | -9.66 | 48.33 | 54.84% | -12.96% |
ACAD | 3.5B | 631.9M | -10.80% | 43.56% | -23.56 | 5.55 | 23.54% | 31.53% |
AXSM | 3.3B | 223.4M | 11.07% | -7.88% | -16.26 | 14.69 | - | -26.24% |
ARWR | 2.6B | 240.7M | -11.66% | -25.68% | -12.44 | 10.6 | -1.03% | -16.59% |
| SMALL-CAP | ||||||||
CPRX | 1.5B | 348.4M | 7.85% | -14.88% | 24.07 | 4.29 | 81.69% | -7.29% |
NVAX | 662.5M | 1.0B | -19.01% | -66.75% | -1.21 | 0.63 | -43.15% | 58.48% |
INO | 100.5M | 6.4M | -2.56% | -78.77% | -0.61 | 15.6 | -44.11% | 50.48% |
IBIO | 42.3M | - | 410.00% | -4.38% | -0.65 | - | - | -29.23% |
CRBP | 26.3M | - | 17.86% | 4717.52% | -0.55 | - | - | -13.74% |
Senti Biosciences, Inc. News
Latest updates
Financials for Senti Biosciences, Inc.
Income Statement (Last 12 Months)(In Thousands)
| Income Statement (Quarterly) | (In Thousands) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 |
| Revenue | -63.9% | 338 | 937 | 1,286 | 59.00 | 1,766 | 1,358 | 1,104 | 793 | 1,103 | 793 | 72.00 | - |
| Operating Expenses | 114.9% | 44,214 | 20,572 | 21,120 | 20,074 | 18,851 | 23,129 | 12,862 | 11,678 | 12,526 | 9,789 | 9,214 | - |
| S&GA Expenses | -2.0% | 9,431 | 9,620 | 9,802 | 10,912 | 10,795 | 13,882 | 5,259 | 5,269 | 7,116 | 4,554 | 4,311 | - |
| R&D Expenses | -17.0% | 9,092 | 10,952 | 11,318 | 9,162 | 8,056 | 9,247 | 7,603 | 6,409 | 5,410 | 5,235 | 4,903 | - |
| Net Income | 20.2% | -14,923 | -18,697 | -18,722 | -18,210 | -16,640 | -11,552 | -11,808 | -10,904 | -11,406 | -12,007 | -21,002 | - |
| Net Income Margin | 100.0% | - | -17.85* | -14.57* | -13.58* | -7.69* | -8.02* | -9.64* | -13.60* | -17.85* | -27.76* | -68.97* | -35.09* |
| Free Cashflow | 100.0% | - | -17,344 | -22,811 | -17,539 | -24,337 | -16,955 | -17,439 | -4,080 | -1,044 | -1,354 | -206 | -6,333 |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q2 | 2021Q1 | 2021Q1 | 2020Q4 |
| Assets | -8.3% | 132 | 144 | 161 | 181 | 189 | 202 | 92.00 | 97.00 | 232 | 232 | 232 | 171 | 110 | 48.00 |
| Current Assets | 24.4% | 79.00 | 63.00 | 81.00 | 103 | 120 | 144 | 45.00 | 60.00 | 2.00 | 2.00 | 2.00 | - | - | 32.00 |
| Cash Equivalents | 24.7% | 46.00 | 37.00 | 32.00 | 58.00 | 115 | 140 | 38.00 | 59.00 | 74.00 | 83.00 | 2.00 | 26.00 | - | 31.00 |
| Net PPE | -55.2% | 26.00 | 59.00 | 59.00 | 56.00 | 47.00 | 36.00 | 24.00 | 12.00 | - | - | - | - | - | 3.00 |
| Liabilities | 5.7% | 49.00 | 46.00 | 49.00 | 54.00 | 49.00 | 48.00 | 42.00 | 36.00 | 8.00 | 8.00 | 8.00 | 11.00 | 14.00 | 17.00 |
| Current Liabilities | -3.0% | 10.00 | 10.00 | 13.00 | 18.00 | 16.00 | 18.00 | 18.00 | 15.00 | 0.00 | 0.00 | 0.00 | - | - | 5.00 |
| Shareholder's Equity | -14.9% | 83.00 | 97.00 | 112 | 127 | 140 | 154 | -121 | -111 | - | 5.00 | - | 0.00 | - | - |
| Retained Earnings | -7.1% | -225 | -210 | -192 | -173 | -155 | -138 | -126 | -115 | -6.52 | -6.23 | -6.00 | 0.00 | 0.00 | -59.76 |
| Additional Paid-In Capital | 0.1% | 309 | 308 | 304 | 301 | 295 | 293 | 5.00 | 4.00 | - | - | - | 0.00 | 0.00 | 1.00 |
| Accumulated Depreciation | 26.7% | 5.00 | 4.00 | 3.00 | 3.00 | 3.00 | 2.00 | 2.00 | 2.00 | - | - | - | - | - | 1.00 |
| Shares Outstanding | 0.0% | 44.00 | 44.00 | 44.00 | 44.00 | 44.00 | 13.00 | 3.00 | 3.00 | 3.00 | 3.00 | - | 15.00 | 5.00 | 15.00 |
Cashflow (Last 12 Months)(In Millions)
| Cashflow (Quarterly) | (In Thousands) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2021Q1 | 2020Q4 |
| Cashflow From Operations | -12.5% | -15,379 | -13,675 | -16,304 | -9,006 | -10,136 | -5,695 | -10,059 | -11,971 | -8,805 | -934 | -8,365 | - | - |
| Share Based Compensation | -88.1% | 409 | 3,434 | 3,763 | 4,216 | 2,290 | 9,225 | 661 | 735 | 626 | 562 | 372 | - | - |
| Cashflow From Investing | 15.3% | 21,142 | 18,331 | -9,497 | -49,118 | -14,201 | -11,260 | -7,380 | - | - | -230,000 | -206 | - | - |
| Cashflow From Financing | -108.2% | -23.00 | 281 | -35.00 | 876 | -485 | 118,615 | -455 | - | - | 232,032 | 3,558 | - | - |
SNTI Income Statement
2023-09-30Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
| Revenue | ||||
| Contract revenue | $ 255 | $ 1,516 | $ 1,978 | $ 3,477 |
| Grant income | 83 | 250 | 583 | 750 |
| Total revenue | 338 | 1,766 | 2,561 | 4,227 |
| Operating expenses | ||||
| Research and development (included related party cost of $1,186, $–, $1,186 and $–, respectively) | 9,092 | 6,519 | 23,028 | 21,108 |
| General and administrative | 9,431 | 9,995 | 27,871 | 28,409 |
| Impairment of property and equipment | 25,691 | 0 | 25,691 | 0 |
| Total operating expenses | 44,214 | 16,514 | 76,590 | 49,517 |
| Loss from operations | (43,876) | (14,748) | (74,029) | (45,290) |
| Other income (expense) | ||||
| Interest income, net | 583 | 542 | 2,438 | 573 |
| Change in fair value of contingent earnout liability | 0 | (99) | 207 | 8,779 |
| Gain on extinguishment of convertible notes | 0 | 0 | 0 | 1,289 |
| GeneFab sublease income - related party | 899 | 0 | 899 | 0 |
| Other income (expense) | (14) | 2 | (26) | (28) |
| Total other income (expense), net | 7,261 | 445 | 9,311 | 10,613 |
| Net loss from continuing operations | (36,615) | (14,303) | (64,718) | (34,677) |
| Net income (loss) from discontinued operations | 21,692 | (2,337) | 12,376 | (5,323) |
| Net loss | (14,923) | (16,640) | (52,342) | (40,000) |
| Other comprehensive loss | ||||
| Unrealized loss on investments | 0 | 0 | (1) | 0 |
| Comprehensive loss | $ (14,923) | $ (16,640) | $ (52,343) | $ (40,000) |
| Net loss per share from continuing operations, basic (in dollars per share) | $ (0.83) | $ (0.33) | $ (1.46) | $ (1.73) |
| Net loss per share from continuing operations, diluted (in dollars per share) | (0.83) | (0.33) | (1.46) | (1.73) |
| Net income (loss) per share from discontinued operations, basic (in dollars per share) | 0.49 | (0.05) | 0.28 | (0.26) |
| Net income (loss) per share from discontinued operations, diluted (in dollars per share) | 0.49 | (0.05) | 0.28 | (0.26) |
| Net loss per share, basic (in dollars per share) | (0.34) | (0.38) | (1.18) | (1.99) |
| Net loss per share, diluted (in dollars per share) | $ (0.34) | $ (0.38) | $ (1.18) | $ (1.99) |
| Weighted-average shares outstanding, basic (in shares) | 44,473,400 | 43,424,172 | 44,275,741 | 20,150,459 |
| Weighted-average shares outstanding, diluted (in shares) | 44,473,400 | 43,424,172 | 44,275,741 | 20,150,459 |
| GeneFab Option | ||||
| Other income (expense) | ||||
| Change in fair value | $ 5,629 | $ 0 | $ 5,629 | $ 0 |
| GeneFab Note Receivable | ||||
| Other income (expense) | ||||
| Change in fair value | 287 | 0 | 287 | 0 |
| GeneFab Economic Share | ||||
| Other income (expense) | ||||
| Change in fair value | $ (123) | $ 0 | $ (123) | $ 0 |
SNTI Balance Sheet
2023-09-30Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Sep. 30, 2023 | Dec. 31, 2022 |
|---|---|---|
| Assets | ||
| Cash and cash equivalents | $ 39,430 | $ 57,621 |
| Short-term investments | 0 | 40,942 |
| Current assets of discontinued operations | 0 | 209 |
| Total current assets | 79,007 | 102,579 |
| Restricted cash | 6,398 | 3,366 |
| GeneFab receivable - related party, net of current portion | 1,056 | 0 |
| Property and equipment, net | 26,433 | 51,361 |
| Operating lease right-of-use assets | 17,018 | 18,418 |
| GeneFab Economic Share - related party | 1,677 | 0 |
| Other long-term assets | 177 | 283 |
| Noncurrent assets of discontinued operations | 0 | 4,785 |
| Total assets | 131,766 | 180,792 |
| Liabilities and Stockholders’ Equity | ||
| Accounts payable | 1,991 | 1,370 |
| Finance lease liabilities, current portion | 96 | 0 |
| Early exercise liability, current portion | 135 | 135 |
| Deferred revenue | 0 | 799 |
| GeneFab sublease deferred income - related party | 1,047 | 0 |
| Accrued expenses and other current liabilities | 4,043 | 12,576 |
| Operating lease liabilities | 2,586 | 1,988 |
| Current liabilities of discontinued operations | 216 | 1,185 |
| Total current liabilities | 10,114 | 18,053 |
| Finance lease liabilities, net of current portion | 25 | 0 |
| Operating lease liabilities, net of current portion | 34,606 | 35,103 |
| Contingent earnout liability | 20 | 227 |
| GeneFab Option - related party | 4,020 | 0 |
| Early exercise liability, net of current portion | 45 | 146 |
| Total liabilities | 48,830 | 53,529 |
| Commitments and contingencies (Note 12) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized at September 30, 2023 and December 31, 2022; zero shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively | 0 | 0 |
| Common stock, $0.0001 par value; 500,000,000 shares authorized at September 30, 2023 and December 31, 2022; 44,477,666 and 44,062,534 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively | 4 | 4 |
| Additional paid-in capital | 308,560 | 300,544 |
| Accumulated other comprehensive income | 0 | 1 |
| Accumulated deficit | (225,628) | (173,286) |
| Total stockholders’ equity | 82,936 | 127,263 |
| Total liabilities and stockholders’ equity | 131,766 | 180,792 |
| Nonrelated Party | ||
| Assets | ||
| Accounts receivable | 138 | 626 |
| Prepaid expenses and other current assets | 3,643 | 3,181 |
| Related Party | ||
| Assets | ||
| Accounts receivable | 18,482 | 0 |
| Prepaid expenses and other current assets | $ 17,314 | $ 0 |
| CEO | Dr. Timothy K. Lu M.D., Ph.D. |
|---|---|
| WEBSITE | www.sentibio.com |
| EMPLOYEES | 122 |